{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:14:55Z","timestamp":1784369695728,"version":"3.55.0"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,31]]},"DOI":"10.18632\/oncotarget.14139","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T01:36:04Z","timestamp":1482888964000},"page":"8406-8419","source":"Crossref","is-referenced-by-count":37,"title":["Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness <i>in vivo<\/i>"],"prefix":"10.18632","volume":"8","author":[{"given":"Laura E.","family":"Wright","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Harhash","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wende M.","family":"Kozlow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Waning","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna N.","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"She","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutha K.","family":"John","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreemala","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryla","family":"Niewolna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Physiology, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid S.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Guise","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,25]]},"reference":[{"key":"1","first-page":"277","article-title":"Cancer statistics","volume":"60","author":"Ward","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","article-title":"Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer","volume":"2","author":"McGuire","year":"1984","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors","volume":"320","author":"Shibatga","year":"1989","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Norton","year":"2003","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Gray","year":"2015","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/endo.142.11.8547","article-title":"Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives","volume":"142","author":"Davis","year":"2001","journal-title":"Endocrinology"},{"key":"7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Smith","year":"2007","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guidelines: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Solky","year":"2010","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Winer","year":"2016","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-007-9774-6","article-title":"Prospective characterization of musculoskeletal symptoms in early breast cancer patients treated with aromatase inhibitors","volume":"111","author":"Hayes","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdq699","article-title":"Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis","volume":"22","author":"Verschueren","year":"2011","journal-title":"Annals Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-011-1351-3","article-title":"Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer","volume":"126","author":"Pritchard","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"13","first-page":"2767","article-title":"Aromatase inhibitors and arthralgia","volume":"19","author":"Leonard","year":"2001","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Storniolo","year":"2012","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/jco.2006.24.18_suppl.551","article-title":"Clinical features of joint symptoms observed in the \u2018Arimedex,\u2019 Tamoxifen, Alone or in Combination (ATAC) trial","volume":"24","author":"Buzdar","year":"2006","journal-title":"J Clin Oncol"},{"key":"16","first-page":"2381","article-title":"Exemestane for breast-cancer prevention in post-menopausal women","volume":"364","author":"Garber","year":"2010","journal-title":"N Engl J Med"},{"key":"17","first-page":"1401","article-title":"Aromatase inhibitors-associated musculoskeletal symptoms: etiology and strategies for management","volume":"22","author":"Stearns","year":"2008","journal-title":"Oncology"},{"key":"18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i1.20","article-title":"Cancer treatment-related bone disease","volume":"19","author":"Guise","year":"2009","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"19","first-page":"5466","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Pritchard","year":"2008","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Guise","year":"2011","journal-title":"Nature Rev Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1138\/20110487","article-title":"Proteolytic enzymes in metastatic bone disease","volume":"8","author":"Cher","year":"2011","journal-title":"IBMS BoneKEy"},{"key":"22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcp.22159","article-title":"Regulation of adult bone turnover by sex steroids","volume":"224","author":"Gabet","year":"2010","journal-title":"J Cell Physiol"},{"key":"23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.22232","article-title":"Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis","volume":"45","author":"Brooks","year":"2012","journal-title":"Muscle Nerve"},{"key":"24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcdb.2015.11.007","article-title":"Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling","volume":"49","author":"Guise","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"TGF\u03b2 mediates muscle weakness associated with bone metastases","volume":"21","author":"Khatiwada","year":"2015","journal-title":"Nature Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/endo-28-5-747","article-title":"The mouse uterine weight method for the assay of estrogens","volume":"28","author":"Koch","year":"1941","journal-title":"Endocrinology"},{"key":"27","first-page":"804","article-title":"Murine models of breast cancer bone metastases","volume":"5","author":"Sterling","year":"2016","journal-title":"BoneKEy Rep"},{"key":"28","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanism of action","volume":"97","author":"Fleisch","year":"1996","journal-title":"J Clin Invest"},{"key":"29","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/art.24907","article-title":"Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis","volume":"60","author":"Westerblad","year":"2009","journal-title":"Arthritis Rheum"},{"key":"30","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1078-0432.CCR-14-0576","article-title":"The microenvironment matters: estrogen deficiency fuels cancer bone metastases","volume":"20","author":"Guise","year":"2014","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential antitumor activity in pre- and postmenopausal bone microenvironment in vivo","volume":"20","author":"Holen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/en.2004-1211","article-title":"Bone turnover mediates preferential localization of prostate cancer in the skeleton","volume":"146","author":"McCauley","year":"2005","journal-title":"Endocrinology"},{"key":"33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Holen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Croucher","year":"2001","journal-title":"Br J Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Gaunt","year":"2011","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Paija","year":"2013","journal-title":"Ann Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomized trial","volume":"12","author":"Eiermann","year":"2011","journal-title":"Lancet Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/bcr2349","article-title":"Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells","volume":"11","author":"Kasimir-Bauer","year":"2009","journal-title":"Breast Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/8756-3282(91)90059-R","article-title":"Incidence, prevalence and distribution of bone metastases","volume":"12","author":"Tubiana-Hulin","year":"1991","journal-title":"Bone"},{"key":"40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000087282","article-title":"Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women","volume":"69","author":"Gradishar","year":"2005","journal-title":"Oncology"},{"key":"41","first-page":"186","article-title":"Changes in muscle mass and strength after menopause","volume":"9","author":"Dionne","year":"2009","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/cs0840095","article-title":"Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy","volume":"84","author":"Woledge","year":"1993","journal-title":"Clin Sci (Lond)"},{"key":"43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/cs0960357","article-title":"Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women","volume":"96","author":"Woledge","year":"1999","journal-title":"Clin Sci (Lond)"},{"key":"44","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"M\u00fcller","year":"2010","journal-title":"J Bone Miner Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:46:31Z","timestamp":1594831591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,25]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,1,31]]}},"alternative-id":["14139","28039445"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14139","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,25]]}}}